Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
QLT Inc |
---|---|
Information provided by: | QLT Inc |
ClinicalTrials.gov Identifier: | NCT00042302 |
To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + paclitaxel/carboplatin. To compare the effects of tariquidar/paclitaxel/carboplatin with placebo/paclitaxel/carboplatin on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.
Condition | Intervention | Phase |
---|---|---|
Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer |
Procedure: Chemotherapy Drug: tariquidar + paclitaxel/carboplatin Drug: placebo + paclitaxel/carboplatin |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | TQD LUNG 001 |
Study First Received: | July 26, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00042302 |
Health Authority: | United States: Food and Drug Administration |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Paclitaxel Lung Neoplasms |
Lung Diseases Carboplatin Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Mitosis Modulators Tubulin Modulators Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |